EU MDR第17条の調和：持続可能な周術期ケアに向けた規制断片化克服への視点
Harmonizing Article 17 of the EU MDR: a Perspective on Overcoming Regulatory Fragmentation for Sustainable Perioperative Care (原題)
Federica Pirro, Viola Vahle, Daniel Vukelich
🤖 gxceed AI 要約
日本語
EU医療機器規則（MDR）第17条は単回使用医療機器の第三者再製造の監督を加盟国に委ね、国ごとの規則が錯綜し再製造の拡大を妨げている。アイルランドの実施事例とイタリアの頓挫事例の対比から、規制断片化が病院の持続可能な循環調達の実装に大きな行政・法的障壁となることを示す。EU全域での調和と標準化、第17条の早急な改正が、医療部門のGHG削減とケアコスト管理の両立に不可欠と結論づける。
English
EU MDR Article 17 delegates oversight of single-use device remanufacturing to Member States, creating fragmented national rules that block scalability. Contrasting an implemented Irish initiative with an aborted Italian proposal shows regulatory fragmentation imposes major administrative and legal barriers to circular hospital procurement. The authors urge EU-wide harmonization and urgent revision of Article 17 to cut healthcare emissions while managing care costs.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本では医療機器の再製造・再利用は薬機法の枠組みで限定的に議論される段階にあり、EUの規制調和の議論は、循環調達とScope 3排出削減を両立させる制度設計の先行事例として参考になる。特に病院の調達部門がサプライチェーン排出削減とコスト管理をどう整合させるかの示唆がある。
In the global GX context
This adds a healthcare-sector case to the global circular procurement and Scope 3 discussion, showing how fragmented medical device regulation undermines emissions reduction. It is relevant to CSRD-driven supply-chain disclosure and to regulators weighing harmonized rules for remanufacturing as a decarbonization lever.
👥 読者別の含意
🔬研究者:医療部門の循環経済と規制断片化が持続可能調達の実装に与える影響を分析する事例研究として有用。
🏢実務担当者:病院・医療機関の調達担当が、再製造品導入時の国別規制リスクとコスト・排出削減のトレードオフを検討する材料になる。
🏛政策担当者:医療機器規制の調和と循環調達促進のため、第17条のような加盟国委任規定の見直しを検討する根拠を提供する。
📄 Abstract（原文）
Background: Healthcare systems across Europe face a dual challenge: reducing their environmental footprint while managing increasing patient care complexity and rising financial pressure. Third-party remanufacturing of single-use medical devices (SUDs) offers a circular economy solution to mitigate healthcare emissions, divert waste, and lower procurement costs. However, its implementation across the European Union remains constrained. Article 17 of the European Union Medical Device Regulation (MDR 2017/745) delegates regulatory oversight of remanufacturing to individual Member States, creating a fragmented landscape of conflicting national rules that impedes scalability of remanufacturing as sustainable clinical practice. Methods: This Perspective article synthesizes current regulatory challenges and reflects upon two illustrative, contrasting perioperative experiences -in Ireland and Italy- to examine how national regulatory environments influence the feasibility of clinical sustainability initiatives. Results: The contrast between the implemented initiative in Ireland and the aborted proposal in Italy suggests that national regulatory fragmentation creates substantial administrative and legal barriers for hospital systems attempting to implement sustainable and circular procurement practices. Conclusion: Harmonizing remanufacturing regulations across Europe is essential to reduce greenhouse gas emissions from the health sector while managing the cost of care. An urgent revision of Article 17 is required to establish EU-wide harmonization and standardization, unlocking potential environmental and economic benefits for perioperative care across Europe.
🔗 Provenance — このレコードを発見したソース
- semanticscholar https://doi.org/10.61440/jmcns.2026.v4.127first seen 2026-09-29 05:41:36
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。